Skip to content
stoqly

Sarepta Therapeutics, Inc.

SRPT Nasdaq Pharmaceutical Preparations Financials FY2016–FY2025

Revenue Total sales reported in the income statement.
$2.2B
15.6% vs prior year
Operating margin Operating income as a share of revenue.
−31.8%
43.3 pts
Net income Profit after all expenses, interest and tax.
−$713M
403.3%
Free cash flow Cash from operations minus capital spending.
−$307M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−53.7%
68.7 pts
Market cap Last close times the latest diluted share count, so it is approximate.
—
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On −$1.60 EPS (TTM)

What Sarepta Therapeutics, Inc. does

No business description yet.

Legal name
Sarepta Therapeutics, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Mar 2, 2026
Accession · CIK
0001193125-26-084144
0000873303

Revenue and margins

Sarepta Therapeutics, Inc. had $2.2B of revenue in fiscal 2025, up 15.6% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$307M in fiscal 2025, −14.0% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Sarepta Therapeutics, Inc. returned $25.0M to shareholders in fiscal 2025. The diluted share count fell 7.2%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Sarepta Therapeutics, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $2.1B$2.0B$1.7B$1.4B$940M
Debt incl. finance leases $564M$1.5B$1.2B$1.1B$829M
Net debt / EBITDA ———−0.9x—
Debt / equity 0.6x4.0x1.4x0.7x0.7x
Interest coverage −7.2x————
Current ratio 5.8x4.1x3.9x4.2x2.3x
Quick ratio 5.3x3.8x3.5x3.2x1.5x
Total assets $3.1B$3.1B$3.3B$4.0B$3.3B
Total liabilities $2.2B$2.7B$2.4B$2.4B$2.2B
Shareholders' equity $928M$385M$859M$1.5B$1.1B
Net debt (− = net cash) −$1.6B−$445M−$438M−$218M−$111M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✓ ✕
Cash from operations is positive ✕ ✕ ✕ ✕ ✓ ✕ ✕ ✕ ✕ ✕
Return on assets rose — ✓ ✕ ✕ ✓ ✓ ✕ ✓ ✓ ✕
Cash from operations exceeds net income ✓ ✕ ✕ ✓ ✓ ✕ ✓ ✓ ✕ ✓
Debt fell relative to assets — ✕ ✓ — — — ✕ ✓ ✓ ✓
Current ratio rose — ✓ ✕ ✕ ✓ ✕ ✕ ✕ ✓ ✕
Share count didn't rise — ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✓
Gross margin rose — — — — — — — — — —
Revenue rose relative to assets — ✓ ✓ ✓ ✕ ✓ ✓ ✓ ✓ ✓
F-score — / 33 / 82 / 82 / 74 / 72 / 72 / 84 / 85 / 84 / 8
Accruals ratio −5.1%20.9%1.8%−14.9%−27.5%0.8%−12.0%−1.1%12.2%−13.9%
Altman Z'' −4.543.402.24−1.520.530.62−1.01−0.751.44−2.78

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $5.4M $155M $301M $381M $540M $702M $933M $1.2B $1.9B $2.2B
Gross profit $5.3M — — — — — — — — $2.2B
Research and development $188M $167M $402M $561M $722M $771M $877M $877M $805M $1.5B
Operating income −$267M −$172M −$344M −$706M −$564M −$460M −$536M −$268M $218M −$700M
Interest expense $1.9M $5.8M $33.7M $30.7M $59.9M $63.5M −$53.2M −$22.0M −$18.4M −$38.1M
Pretax income −$267M −$48.6M −$363M −$714M −$553M −$419M −$690M −$520M $261M −$702M
Income tax — $2.1M −$0.7M $1.2M $1.1M −$0.2M $13.5M $15.9M $25.5M $11.2M
Net income −$267M −$50.7M −$362M −$715M −$554M −$419M −$703M −$536M $235M −$713M
Net income to common — — — — — — — −$536M $235M −$713M
Diluted EPS −$5.49 −$0.86 −$5.46 −$9.71 −$7.11 −$5.15 −$8.03 −$5.80 $2.34 −$7.13
Diluted shares 0.05B 0.06B 0.07B 0.07B 0.08B 0.08B 0.09B 0.09B 0.11B 0.10B
Cash flow
Cash from operations −$246M −$232M −$389M −$456M $107M −$443M −$325M −$501M −$206M −$205M
Capital expenditure $5.3M $12.0M $61.2M $59.6M $82.2M $38.5M $30.8M $76.1M $137M $102M
Free cash flow −$251M −$244M −$450M −$516M $25.3M −$482M −$356M −$577M −$343M −$307M
Depreciation and amortization $5.6M $8.1M $12.2M $24.5M $26.9M $38.0M $41.9M $44.4M $37.7M $44.5M
Stock-based compensation $30.0M $30.5M $50.1M $78.6M $108M $114M $233M $183M $184M $123M
Acquisitions — — — $173M — — — — — —
Share buybacks — — — — — — — $0.0M $0.0M $25.0M
Dividends and buybacks — — — — — — — $0.0M $0.0M $25.0M
Balance sheet
Cash and short-term investments $318M $1.1B $1.2B $1.1B $1.9B $2.1B $2.0B $1.7B $1.4B $940M
Total debt $17.7M $431M $421M — — $564M $1.5B $1.2B $1.1B $829M
Current assets $373M $1.2B $1.4B $1.5B $2.5B $2.6B $2.6B $2.6B $3.1B $2.5B
Current liabilities $75.4M $88.3M $174M $265M $416M $453M $620M $654M $732M $1.1B
Inventory $12.8M $83.6M $125M $171M $232M $186M $204M $323M $750M $915M
Property and equipment, net $37.8M $43.2M $97.0M $130M $190M $191M $180M $227M $340M $345M
Intangible assets $8.1M $14.4M $11.6M $12.5M $13.6M $14.2M $7.6M $29.6M $26.9M $28.9M
Total assets $424M $1.3B $1.6B $1.8B $3.0B $3.1B $3.1B $3.3B $4.0B $3.3B
Total liabilities $87.4M $519M $610M $1.0B $2.2B $2.2B $2.7B $2.4B $2.4B $2.2B
Preferred stock — — — — — $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity $337M $789M $1.0B $818M $762M $928M $385M $859M $1.5B $1.1B
Margins
Gross margin 97.6% — — — — — — — — 98.8%
Operating margin −4,920.3% −111.0% −114.1% −185.3% −104.5% −65.5% −57.5% −21.5% 11.5% −31.8%
EBITDA margin −4,816.8% −105.8% −110.1% −178.8% −99.5% −60.1% −53.0% −18.0% 13.4% −29.8%
Net margin −4,930.2% −32.8% −120.2% −187.8% −102.6% −59.7% −75.4% −43.1% 12.4% −32.5%
FCF margin −4,633.1% −157.8% −149.4% −135.5% 4.7% −68.6% −38.2% −46.4% −18.0% −14.0%
Returns
Return on capital −577.1% −96.0% −97.3% — — — — −50.2% 15.0% −53.7%
Return on capital employed −76.5% −14.1% −23.4% −45.3% −22.0% −17.1% −21.4% −10.3% 6.7% −31.0%
Return on equity −79.4% −9.0% −39.7% −77.3% −70.1% −49.6% −107.2% −86.2% 19.7% −53.5%
Return on assets −63.0% −5.9% −24.5% −41.3% −23.1% −13.7% −22.4% −16.8% 6.5% −19.5%
Return on tangible equity −81.3% −6.5% −35.5% −88.8% −74.1% −45.8% −186.4% −64.6% 15.7% −64.2%
Growth
Revenue growth — 2,751.6% 94.7% 26.5% 41.8% 30.0% 32.9% 33.3% 53.0% 15.6%
Net income growth — — — — — — — — — −403.3%
EPS growth — — — — — — — — — −404.7%
FCF growth — — — — — −2,006.5% — — — —
Share count change — 20.8% 12.6% 11.1% 5.9% 4.2% 7.7% 5.5% 16.8% −7.2%
Financial health
Net debt / EBITDA — — — — — — — — −0.9x —
Debt / equity 0.1x 0.5x 0.4x — — 0.6x 4.0x 1.4x 0.7x 0.7x
Interest coverage −141.0x −29.6x −10.2x −23.0x −9.4x −7.2x — — — —
Current ratio 5.0x 13.9x 8.2x 5.5x 6.0x 5.8x 4.1x 3.9x 4.2x 2.3x
Quick ratio 4.8x 13.0x 7.5x 4.9x 5.4x 5.3x 3.8x 3.5x 3.2x 1.5x
Capital allocation
Capex / revenue 98.5% 7.8% 20.3% 15.7% 15.2% 5.5% 3.3% 6.1% 7.2% 4.6%
Stock comp / revenue 552.7% 19.7% 16.7% 20.6% 20.0% 16.2% 25.0% 14.7% 9.7% 5.6%
Quality scores
Piotroski F-score — 3.0 2.0 2.0 4.0 2.0 2.0 4.0 5.0 4.0
Altman Z'' −4.5 3.4 2.2 −1.5 0.5 0.6 −1.0 −0.7 1.4 −2.8
Accruals ratio −5.1% 20.9% 1.8% −14.9% −27.5% 0.8% −12.0% −1.1% 12.2% −13.9%

Source: SEC EDGAR XBRL filings (CIK 0000873303). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open